[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-001", "question": "A 56-year-old man with long-standing type 2 diabetes, CKD stage 3b, and prior NSTEMI presents for routine follow-up. Medications: metformin 500 mg BID, empagliflozin 10 mg daily, lisinopril 20 mg daily, metoprolol succinate 100 mg daily, and high-intensity statin. BP is 118/66 mm Hg, BMI 31 kg/m², A1c 7.2%. eGFR is 37 mL/min/1.73 m², urinary ACR 620 mg/g (persistent over 9 months), potassium 4.6 mEq/L. He has no hyperkalemia history. Which change in therapy is most appropriate to further reduce his cardiorenal risk?", "options": ["Increase empagliflozin to 25 mg daily", "Add finerenone with close potassium monitoring", "Replace lisinopril with sacubitril/valsartan", "Add basal insulin to target A1c <6.5%", "Add a non-dihydropyridine calcium channel blocker"], "answer": "B", "answer_index": 1, "explanation": "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces CV events and CKD progression in diabetics with albuminuric CKD already on ACEi/ARB and SGLT2i and with eGFR >25 and K<4.8. Increasing SGLT2 dose adds minimal incremental renal protection, sacubitril/valsartan is not indicated without HFrEF, tighter glycemic control adds little cardiorenal benefit with more risk, and non-DHP CCBs do not provide proven outcome benefit here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: T2DM with CKD stage 3b (eGFR 37 mL/min), persistent albuminuria (ACR 620 mg/g), prior NSTEMI, already on ACEi and SGLT2i, potassium 4.6 mEq/L without hyperkalemia history. These precisely match finerenone trial entry criteria (eGFR ≥25, albuminuria, background RAAS inhibition). The keyed answer B (add finerenone) is uniquely defensible per FIDELIO-DKD/FIGARO-DKD showing cardiorenal risk reduction in this population. Competing options are clearly inferior: empagliflozin dose escalation (A) offers minimal incremental benefit; sacubitril/valsartan (C) lacks HFrEF indication; intensive glycemic control (D) increases hypoglycemia risk without cardiorenal advantage; non-DHP CCBs (E) lack outcome evidence. No logical contradictions or underspecification. Medical accuracy is excellent and guideline-concordant (KDIGO 2022, ADA 2023). Minimal fix: None required; item is board-ready.\",\n\"medical_accuracy_score\": 5,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: T2DM with CKD stage 3b (eGFR 37 mL/min), persistent albuminuria (ACR 620 mg/g), prior NSTEMI, already on ACEi and SGLT2i, potassium 4.6 mEq/L without hyperkalemia history. These precisely match finerenone trial entry criteria (eGFR ≥25, albuminuria, background RAAS inhibition). The keyed answer B (add finerenone) is uniquely defensible per FIDELIO-DKD/FIGARO-DKD showing cardiorenal risk reduction in this population. Competing options are clearly inferior: empagliflozin dose escalation (A) offers minimal incremental benefit; sacubitril/valsartan (C) lacks HFrEF indication; intensive glycemic control (D) increases hypoglycemia risk without cardiorenal advantage; non-DHP CCBs (E) lack outcome evidence. No logical contradictions or underspecification. Medical accuracy is excellent and guideline-concordant (KDIGO 2022, ADA 2023). Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-002", "question": "A 4-year-old boy is brought to the ED with 2 days of fever, abdominal pain, and vomiting. PMH includes Kawasaki disease at 11 months treated with IVIG and aspirin; echocardiography then showed a 7-mm giant aneurysm of the left anterior descending coronary artery, which has since regressed to normal dimensions by age 3. He is off antiplatelets and asymptomatic at baseline. Current vitals: T 39.2°C, HR 145/min, BP 82/48 mm Hg, RR 30/min, SpO2 95% RA. He appears ill and mottled with cool extremities. ECG shows sinus tachycardia with ST-segment depression in V4-V6. High-sensitivity troponin is mildly elevated. Bedside echo shows mild global LV dysfunction (EF 45%), no visible aneurysm. After fluid resuscitation and initiation of broad-spectrum antibiotics, which management step is most appropriate now?", "options": ["Re-treat with high-dose IVIG and start high-dose aspirin", "Obtain emergent coronary CT angiography and start IV heparin", "Start IV milrinone and low-dose aspirin without additional imaging", "Start IV methylprednisolone plus IVIG and transfer for ECMO standby", "Begin norepinephrine for septic shock and defer cardiac-specific therapy"], "answer": "B", "answer_index": 1, "explanation": "Children with prior giant Kawasaki aneurysms remain at risk for thrombosis and stenosis despite angiographic regression; acute coronary syndrome can mimic sepsis. ST depression, hypotension, and troponin elevation warrant urgent coronary imaging (CT angiography) and antithrombotic therapy. Routine retreatment with IVIG is not indicated years later, steroids/ECMO are premature without refractory shock, and treating as isolated sepsis risks missing coronary occlusion.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Key stem clues: prior 7-mm giant LAD aneurysm (lifelong thrombosis risk persists despite echo 'regression'), hypotension/tachycardia after fluids, mottled/cool extremities, ST depression V4-V6, elevated troponin, and mild LV dysfunction—collectively indicating acute coronary syndrome masquerading as sepsis. The keyed answer (B) is uniquely defensible: emergent coronary CT angiography rapidly evaluates the previously aneurysmal LAD for thrombosis/stenosis, and IV heparin provides immediate antithrombotic therapy. No logical issues: the vignette is internally consistent, allows clear discrimination, and the key matches the single best option. Medical accuracy is excellent (score 5): reflects established pediatric cardiology knowledge that giant aneurysm regression on imaging does not eliminate histologic pathology or late coronary event risk, and management aligns with current standards for suspected coronary occlusion. Alternative options are clearly inferior: A is contraindicated years later, C treats heart failure without diagnosing ischemia, D is overly aggressive without refractory shock, and E misses the coronary etiology. No fix required; item is board-ready as written.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues: prior 7-mm giant LAD aneurysm (lifelong thrombosis risk persists despite echo 'regression'), hypotension/tachycardia after fluids, mottled/cool extremities, ST depression V4-V6, elevated troponin, and mild LV dysfunction—collectively indicating acute coronary syndrome masquerading as sepsis. The keyed answer (B) is uniquely defensible: emergent coronary CT angiography rapidly evaluates the previously aneurysmal LAD for thrombosis/stenosis, and IV heparin provides immediate antithrombotic therapy. No logical issues: the vignette is internally consistent, allows clear discrimination, and the key matches the single best option. Medical accuracy is excellent (score 5): reflects established pediatric cardiology knowledge that giant aneurysm regression on imaging does not eliminate histologic pathology or late coronary event risk, and management aligns with current standards for suspected coronary occlusion. Alternative options are clearly inferior: A is contraindicated years later, C treats heart failure without diagnosing ischemia, D is overly aggressive without refractory shock, and E misses the coronary etiology. No fix required; item is board-ready as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-003", "question": "A 32-year-old woman presents with 3 weeks of migratory polyarthritis, pleuritic chest pain, and low-grade fever. Exam: malar rash sparing nasolabial folds, small bilateral pleural effusions, and mild synovitis of wrists and MCPs. Labs: Hb 10.4 g/dL, platelets 145,000/µL, WBC 3,200/µL, Cr 0.8 mg/dL, urine protein/Cr ratio 0.2, AST/ALT mildly elevated. ESR 75 mm/h, CRP 2.1 mg/dL. ANA 1:640 homogeneous, anti-dsDNA high, low C3/C4. Anti-phospholipid antibodies are negative on two occasions 12 weeks apart. Echocardiogram shows a small pericardial effusion without tamponade. She has a confirmed positive pregnancy test at 6 weeks gestation. Which of the following is the most appropriate initial treatment strategy?", "options": ["Start high-dose prednisone plus mycophenolate mofetil", "Start hydroxychloroquine and low-moderate dose prednisone", "Start methotrexate and high-dose NSAIDs", "Defer immunosuppression and treat with low-dose aspirin alone", "Start belimumab and discontinue hydroxychloroquine once controlled"], "answer": "B", "answer_index": 1, "explanation": "This is new-onset SLE with non-organ-threatening disease in early pregnancy; hydroxychloroquine is recommended in all pregnant SLE patients and improves maternal and fetal outcomes. Low-moderate dose prednisone addresses serositis and arthritis with acceptable fetal safety. Mycophenolate and methotrexate are teratogenic, aspirin alone is inadequate for active disease, and belimumab is not first-line in new, non-severe SLE in pregnancy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (Valid). The vignette describes new-onset SLE with non-organ-threatening disease in early pregnancy (6 weeks gestation), presenting with polyarthritis, pleuritis, pericardial effusion, mild cytopenias, and positive serologies. Key discriminating features are the early gestational age and active disease requiring safe immunosuppression. The keyed answer (B) is uniquely defensible: hydroxychloroquine is strongly recommended for all pregnant SLE patients per ACR/EULAR guidelines to improve outcomes and prevent flares, while low-moderate dose prednisone effectively controls serositis and arthritis with acceptable fetal safety. All alternatives are clearly incorrect: mycophenolate (A) and methotrexate (C) are absolutely teratogenic and contraindicated; high-dose NSAIDs (C) are avoided in pregnancy; aspirin alone (D) is inadequate for active disease and only indicated for APA-positive patients (she is negative); belimumab (E) is not first-line for non-severe disease, and discontinuing HCQ is contrary to standard practice. No internal contradictions or missing critical details. Medical accuracy is gold-standard. No fix required.\",\n\"medical_accuracy_score\": 5,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). The vignette describes new-onset SLE with non-organ-threatening disease in early pregnancy (6 weeks gestation), presenting with polyarthritis, pleuritis, pericardial effusion, mild cytopenias, and positive serologies. Key discriminating features are the early gestational age and active disease requiring safe immunosuppression. The keyed answer (B) is uniquely defensible: hydroxychloroquine is strongly recommended for all pregnant SLE patients per ACR/EULAR guidelines to improve outcomes and prevent flares, while low-moderate dose prednisone effectively controls serositis and arthritis with acceptable fetal safety. All alternatives are clearly incorrect: mycophenolate (A) and methotrexate (C) are absolutely teratogenic and contraindicated; high-dose NSAIDs (C) are avoided in pregnancy; aspirin alone (D) is inadequate for active disease and only indicated for APA-positive patients (she is negative); belimumab (E) is not first-line for non-severe disease, and discontinuing HCQ is contrary to standard practice. No internal contradictions or missing critical details. Medical accuracy is gold-standard. No fix required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-004", "question": "A 61-year-old man with obesity and hypertension presents with exertional dyspnea and occasional chest tightness. Resting ECG is normal. Transthoracic echocardiogram shows EF 60%, mild concentric LVH, and no valvular disease. He undergoes a standard exercise treadmill test using Bruce protocol. At stage 3, he develops 2-mm horizontal ST depression in leads V4-V6 and II, III, aVF with peak HR 142/min (89% of predicted). He has no chest pain and BP rises appropriately. Nuclear perfusion imaging done concurrently shows normal perfusion and normal LV function at rest and stress. Coronary CT angiography reveals a short left main with separate LAD and LCx ostia, no atherosclerotic plaque, and a myocardial bridge in the mid-LAD with 80% systolic compression but preserved diastolic lumen. Which is the best next step in management?", "options": ["Start high-dose beta-blocker therapy and avoid further ischemic workup", "Refer for percutaneous coronary intervention with stenting of the bridged segment", "Order invasive coronary angiography with pressure-wire assessment during dobutamine stress", "Schedule surgical myotomy of the myocardial bridge", "Reassure the patient and no further follow-up is required"], "answer": "C", "answer_index": 2, "explanation": "The discordance between ischemic ST changes and normal perfusion imaging in the setting of a significant myocardial bridge raises concern for dynamic flow limitation, especially at higher heart rates not reached on standard testing. Invasive angiography with physiologic assessment (FFR/iFR or diastolic FFR during inotropic stress) clarifies hemodynamic significance and guides need for intensified medical or surgical therapy. Empiric high-dose beta-blockers or surgery without confirming significance is premature, and PCI in bridged segments has high complication rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"The vignette describes a 61‑year‑old man with obesity, hypertension, exertional dyspnea, and occasional chest tightness. Resting ECG and echocardiogram are normal. Exercise treadmill testing shows 2‑mm horizontal ST depression in leads V4‑V6 and II, III, aVF at a peak HR of 142 bpm (≈89 % predicted) without chest pain. Nuclear perfusion imaging is normal. Coronary CT angiography reveals a mid‑LAD myocardial bridge with 80 % systolic compression but preserved diastolic lumen and no plaque. The key issue is whether the bridge is hemodynamically significant and explains the discordant ischemic ECG changes. The answer key selects invasive coronary angiography with pressure‑wire assessment during dobutamine stress (option C). This directly measures dynamic flow limitation across the bridge and is supported by current literature as the appropriate next step when non‑invasive tests are discordant. Options A, B, D, and E are less appropriate: empiric high‑dose β‑blockade without confirming significance is not guideline‑concordant first‑line therapy, PCI in a bridged segment carries high complication rates, surgical myotomy is premature without proven hemodynamic relevance, and simple reassurance ignores objective ST‑segment changes. Minor wording issues (e.g., \\\"higher heart rates not reached on standard testing\\\") do not undermine the overall reasoning. Thus, the item supports a single best answer and the key is correct.\",\n\"medical_accuracy_score\": 3,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a 61‑year‑old man with obesity, hypertension, exertional dyspnea, and occasional chest tightness. Resting ECG and echocardiogram are normal. Exercise treadmill testing shows 2‑mm horizontal ST depression in leads V4‑V6 and II, III, aVF at a peak HR of 142 bpm (≈89 % predicted) without chest pain. Nuclear perfusion imaging is normal. Coronary CT angiography reveals a mid‑LAD myocardial bridge with 80 % systolic compression but preserved diastolic lumen and no plaque. The key issue is whether the bridge is hemodynamically significant and explains the discordant ischemic ECG changes. The answer key selects invasive coronary angiography with pressure‑wire assessment during dobutamine stress (option C). This directly measures dynamic flow limitation across the bridge and is supported by current literature as the appropriate next step when non‑invasive tests are discordant. Options A, B, D, and E are less appropriate: empiric high‑dose β‑blockade without confirming significance is not guideline‑concordant first‑line therapy, PCI in a bridged segment carries high complication rates, surgical myotomy is premature without proven hemodynamic relevance, and simple reassurance ignores objective ST‑segment changes. Minor wording issues (e.g., \"higher heart rates not reached on standard testing\") do not undermine the overall reasoning. Thus, the item supports a single best answer and the key is correct.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-005", "question": "A 28-year-old woman at 36 weeks gestation presents to the ED with severe headache, visual blurring, and nausea. BP is 188/118 mm Hg, HR 96/min. She is agitated and reports seeing flashing lights. Reflexes are brisk with 3+ patellar reflexes and 1-2 beats of clonus. Labs: platelets 102,000/µL, AST 105 U/L, ALT 98 U/L, Cr 1.2 mg/dL, urine protein/Cr ratio 1.0. Shortly after arrival, she has a generalized tonic-clonic seizure lasting 90 seconds, then becomes postictal. Oxygen saturation is 95% on 2 L nasal cannula. Fetal heart monitoring is reassuring. She has already received a 4-g IV loading dose of magnesium sulfate en route. Which is the most appropriate immediate next step after stabilizing airway and breathing?", "options": ["Administer an additional 2-g IV magnesium bolus and start IV labetalol", "Start continuous propofol infusion and emergent head CT before antihypertensives", "Give IV levetiracetam, discontinue magnesium, and proceed to emergent cesarean delivery", "Start nicardipine infusion targeting BP <120/80 mm Hg and delay delivery for 48 hours", "Administer IV diazepam and begin oral labetalol once she awakens"], "answer": "A", "answer_index": 0, "explanation": "She has eclampsia with severe features; magnesium is first-line for seizure control and recurrence prevention, and a repeat bolus is appropriate after a breakthrough seizure on therapy. Rapid parenteral antihypertensive (e.g., IV labetalol) is needed to control severe BP, with expeditious delivery once stabilized. Propofol, levetiracetam alone, aggressive BP lowering to normal, or delaying delivery are not appropriate initial strategies.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). This eclampsia with severe features vignette supports a unique best answer. Key discriminating clues: breakthrough generalized seizure despite 4g magnesium sulfate loading dose, severe hypertension (188/118 mm Hg), thrombocytopenia (102k), elevated transaminases (AST 105, ALT 98), proteinuria, and hyperreflexia with clonus. The keyed answer (A) is defensible: recurrent seizures on magnesium warrant an additional 2-4g bolus per ACOG guidelines, and severe hypertension requires rapid parenteral antihypertensive therapy—IV labetalol is first-line. Alternative options are clearly inferior: B inappropriately delays antihypertensives for head CT and uses propofol over magnesium; C incorrectly discontinues magnesium and uses non-standard levetiracetam; D targets dangerously aggressive BP reduction (<120/80) risking uteroplacental insufficiency and delays delivery; E uses second-line diazepam and inappropriate oral labetalol. No internal contradictions or underspecification. The item accurately reflects current obstetric emergency management: magnesium remains first-line, BP target is <160/110 mm Hg, and delivery is indicated after stabilization. Medical accuracy is excellent. No fix required.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). This eclampsia with severe features vignette supports a unique best answer. Key discriminating clues: breakthrough generalized seizure despite 4g magnesium sulfate loading dose, severe hypertension (188/118 mm Hg), thrombocytopenia (102k), elevated transaminases (AST 105, ALT 98), proteinuria, and hyperreflexia with clonus. The keyed answer (A) is defensible: recurrent seizures on magnesium warrant an additional 2-4g bolus per ACOG guidelines, and severe hypertension requires rapid parenteral antihypertensive therapy—IV labetalol is first-line. Alternative options are clearly inferior: B inappropriately delays antihypertensives for head CT and uses propofol over magnesium; C incorrectly discontinues magnesium and uses non-standard levetiracetam; D targets dangerously aggressive BP reduction (<120/80) risking uteroplacental insufficiency and delays delivery; E uses second-line diazepam and inappropriate oral labetalol. No internal contradictions or underspecification. The item accurately reflects current obstetric emergency management: magnesium remains first-line, BP target is <160/110 mm Hg, and delivery is indicated after stabilization. Medical accuracy is excellent. No fix required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-006", "question": "A 9-year-old boy presents with 3 months of diffuse musculoskeletal pain, morning stiffness lasting 30-45 minutes, and profound fatigue. He was previously athletic but now avoids activity due to pain. Exam shows generalized tenderness over muscles and entheses, mild limitation of lumbar flexion, and no clear joint effusions. No rash, fevers, or weight loss. Labs: CBC, ESR, CRP, CK, aldolase, and TSH are normal. ANA 1:80 speckled, RF negative, HLA-B27 negative. XR of sacroiliac joints and spine are normal. He has fragmented sleep, difficulty focusing at school, and abdominal pain without alarm features. Which strategy is most appropriate to establish the correct diagnosis and direct management?", "options": ["Order whole-body MRI to evaluate for enthesitis-related arthritis or occult malignancy", "Diagnose juvenile fibromyalgia and implement a graded exercise and CBT program", "Perform lumbar puncture and brain MRI to evaluate for CNS vasculitis", "Start a 3-month trial of NSAIDs and low-dose prednisone for suspected JIA", "Order EMG and nerve conduction studies to exclude small fiber neuropathy"], "answer": "B", "answer_index": 1, "explanation": "Chronic widespread pain, normal inflammatory and muscle markers, non-restorative sleep, cognitive complaints, and functional GI symptoms are characteristic of juvenile fibromyalgia. Early diagnosis with emphasis on graded aerobic/strength exercise and cognitive behavioral therapy is key. Whole-body MRI, CNS workup, empiric steroids, or EMG are unnecessary and potentially harmful in this presentation.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). The vignette presents a 9-year-old with chronic widespread pain, profound fatigue, and non-restorative sleep, coupled with completely normal inflammatory markers (ESR, CRP) and muscle enzymes (CK, aldolase), classic for juvenile fibromyalgia. The keyed answer B correctly establishes the clinical diagnosis and directs management toward graded exercise and CBT, which is standard of care. Key discriminating features are the negative laboratory workup and lack of objective inflammatory signs, effectively excluding JIA and myositis. Alternative options are clearly inappropriate: whole-body MRI (A) is excessive without red flags; CNS vasculitis workup (C) lacks clinical justification; empiric NSAIDs/steroids (D) risks harm without evidence of inflammation; EMG (E) is unnecessary without neuropathic symptoms. No internal contradictions or critical missing details prevent a single best answer. Medical accuracy is excellent and consistent with pediatric rheumatology guidelines. Minor point: 30-45 minute morning stiffness is longer than typical for fibromyalgia but does not override the otherwise clear picture. Minimal fix: None required; item is board-ready.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). The vignette presents a 9-year-old with chronic widespread pain, profound fatigue, and non-restorative sleep, coupled with completely normal inflammatory markers (ESR, CRP) and muscle enzymes (CK, aldolase), classic for juvenile fibromyalgia. The keyed answer B correctly establishes the clinical diagnosis and directs management toward graded exercise and CBT, which is standard of care. Key discriminating features are the negative laboratory workup and lack of objective inflammatory signs, effectively excluding JIA and myositis. Alternative options are clearly inappropriate: whole-body MRI (A) is excessive without red flags; CNS vasculitis workup (C) lacks clinical justification; empiric NSAIDs/steroids (D) risks harm without evidence of inflammation; EMG (E) is unnecessary without neuropathic symptoms. No internal contradictions or critical missing details prevent a single best answer. Medical accuracy is excellent and consistent with pediatric rheumatology guidelines. Minor point: 30-45 minute morning stiffness is longer than typical for fibromyalgia but does not override the otherwise clear picture. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-007", "question": "A 63-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) presents with progressive dyspnea and dry cough over 4 months. Medications: methotrexate 20 mg weekly (for 10 years), low-dose prednisone 5 mg daily, and adalimumab for 3 years. She has no fevers or weight loss. Exam reveals bibasilar fine inspiratory crackles and mild digital clubbing. PFTs show FVC 62% predicted, FEV1/FVC 0.85, and DLCO 40% predicted. HRCT of the chest shows subpleural reticulation, traction bronchiectasis, and honeycombing predominantly in the bases, consistent with a usual interstitial pneumonia (UIP) pattern. There are no ground-glass opacities. Which is the most appropriate modification of her RA and lung disease management?", "options": ["Discontinue methotrexate permanently and increase adalimumab dose", "Continue current RA regimen and add nintedanib", "Stop adalimumab and switch to rituximab while continuing methotrexate", "Stop methotrexate and adalimumab, and start high-dose prednisone plus azathioprine", "Add mycophenolate mofetil to current regimen for treatment of ILD"], "answer": "B", "answer_index": 1, "explanation": "This is RA-associated ILD with a UIP pattern, which behaves like idiopathic pulmonary fibrosis and typically does not respond to high-dose immunosuppression. Nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and can be added while stable articular disease is controlled. Routine methotrexate cessation is not clearly beneficial here, and switching biologics or adding mycophenolate is more appropriate for inflammatory (e.g., NSIP) patterns rather than established fibrotic UIP.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\": \"Validity: V. The vignette describes RA-ILD with a definitive UIP pattern (subpleural reticulation, traction bronchiectasis, honeycombing, absent ground-glass opacities) and restrictive physiology (FVC 62%, FEV1/FVC 0.85, DLCO 40%). This fibrotic phenotype behaves like IPF and warrants anti-fibrotic therapy. The keyed answer B is defensible: nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and continuing stable RA therapy is reasonable when articular disease is controlled. Options A, C, D, and E are clearly inferior—increasing adalimumab (A) or switching to rituximab (C) addresses RA activity but not fibrosis; high-dose steroids/azathioprine (D) and mycophenolate (E) target inflammatory ILD patterns (e.g., NSIP) and lack proven benefit in established UIP. No internal contradictions exist, and the options permit clear discrimination. Medical accuracy is sound: the distinction between fibrotic and inflammatory ILD management aligns with ATS/ERS guidance, though MTX cessation in RA-ILD remains debated. The item is clinically realistic and board-relevant. Minimal fix: None required; the item is valid as written.\", \"medical_accuracy_score\": 4, \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. The vignette describes RA-ILD with a definitive UIP pattern (subpleural reticulation, traction bronchiectasis, honeycombing, absent ground-glass opacities) and restrictive physiology (FVC 62%, FEV1/FVC 0.85, DLCO 40%). This fibrotic phenotype behaves like IPF and warrants anti-fibrotic therapy. The keyed answer B is defensible: nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and continuing stable RA therapy is reasonable when articular disease is controlled. Options A, C, D, and E are clearly inferior—increasing adalimumab (A) or switching to rituximab (C) addresses RA activity but not fibrosis; high-dose steroids/azathioprine (D) and mycophenolate (E) target inflammatory ILD patterns (e.g., NSIP) and lack proven benefit in established UIP. No internal contradictions exist, and the options permit clear discrimination. Medical accuracy is sound: the distinction between fibrotic and inflammatory ILD management aligns with ATS/ERS guidance, though MTX cessation in RA-ILD remains debated. The item is clinically realistic and board-relevant. Minimal fix: None required; the item is valid as written.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-008", "question": "A 45-year-old man with poorly controlled type 2 diabetes (A1c 10.8%), BMI 36 kg/m², and mild nonproliferative diabetic retinopathy presents for follow-up. Medications: metformin 1000 mg BID and basal insulin glargine 35 units nightly. He had an episode of acute pancreatitis 3 years ago attributed to severe hypertriglyceridemia (TG 1,800 mg/dL); since then, triglycerides have been controlled around 250-300 mg/dL on fenofibrate. He drinks no alcohol. eGFR is 65 mL/min/1.73 m², AST/ALT are mildly elevated (1.5× ULN), and ultrasound shows fatty liver without biliary disease. He is interested in newer injectable therapies for weight loss and glucose control. Which glucose-lowering agent is most appropriate to add now?", "options": ["Liraglutide", "Semaglutide", "Dulaglutide", "Tirzepatide", "Empagliflozin"], "answer": "E", "answer_index": 4, "explanation": "Given prior pancreatitis, any incretin-based therapy (GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide) carries a theoretical risk of recurrence, and product labels recommend caution or avoidance. An SGLT2 inhibitor such as empagliflozin improves glycemic control, promotes modest weight loss, and provides CV/renal benefits without known pancreatitis signal. His eGFR is adequate, making empagliflozin the safest choice among the listed options.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: C (Contradiction) with secondary M (Multiple answers defensible). The stem explicitly states the patient is interested in 'newer injectable therapies,' yet the keyed answer (empagliflozin) is oral—an internal inconsistency. Medical accuracy: The rationale cites a pancreatitis contraindication for GLP-1 RAs that is outdated; FDA removed this warning, and current ADA/AACE guidelines support GLP-1 RA use after pancreatitis when triglycerides are controlled. This represents a major factual error that misleads learners. Additionally, with A1c 10.8% and BMI 36, GLP-1 RAs (especially semaglutide) or tirzepatide would be more effective for both glycemic control and weight loss than SGLT2 inhibitors, making multiple options equally or more defensible. The item is therefore miskeyed under current standards. Minimal fix: Delete 'injectable' from the stem and revise the rationale to reflect that GLP-1 RAs are not contraindicated; then either select the most potent agent (tirzepatide) for this high A1c/obese patient or provide a nuanced justification for choosing empagliflozin over more effective alternatives.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: C (Contradiction) with secondary M (Multiple answers defensible). The stem explicitly states the patient is interested in 'newer injectable therapies,' yet the keyed answer (empagliflozin) is oral—an internal inconsistency. Medical accuracy: The rationale cites a pancreatitis contraindication for GLP-1 RAs that is outdated; FDA removed this warning, and current ADA/AACE guidelines support GLP-1 RA use after pancreatitis when triglycerides are controlled. This represents a major factual error that misleads learners. Additionally, with A1c 10.8% and BMI 36, GLP-1 RAs (especially semaglutide) or tirzepatide would be more effective for both glycemic control and weight loss than SGLT2 inhibitors, making multiple options equally or more defensible. The item is therefore miskeyed under current standards. Minimal fix: Delete 'injectable' from the stem and revise the rationale to reflect that GLP-1 RAs are not contraindicated; then either select the most potent agent (tirzepatide) for this high A1c/obese patient or provide a nuanced justification for choosing empagliflozin over more effective alternatives.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-009", "question": "A 27-year-old woman is brought to the ED after collapsing during a 10-km race. Bystanders report sudden loss of consciousness without seizure activity; CPR was started immediately, and an AED delivered one shock for ventricular fibrillation with ROSC. She is now awake and oriented. No drugs or supplements; family history notable for an uncle who died suddenly at 32 while swimming, presumed drowning. Vitals: HR 78/min, BP 112/68 mm Hg, normal exam. Labs and echocardiogram are normal. Baseline ECG shows QTc 460 ms, normal QRS, and normal ST-T waves. During recovery from an exercise treadmill test, she develops polymorphic VT that terminates spontaneously; QTc in recovery is 510 ms with late-appearing T waves in V2-V4. Which is the most appropriate next step in management?", "options": ["Implant an ICD and start high-dose beta-blocker therapy", "Start nadolol and schedule left cardiac sympathetic denervation", "Start flecainide in addition to beta-blocker therapy", "Begin verapamil and restrict participation to low-intensity sports", "Perform genetic testing for catecholaminergic polymorphic VT before any therapy"], "answer": "A", "answer_index": 0, "explanation": "This presentation is consistent with congenital long QT syndrome (likely LQT1 or LQT2) with exercise-associated VF arrest and marked QT prolongation in recovery. Survivors of cardiac arrest from LQTS require ICD plus beta-blocker therapy. LCSD or flecainide may be adjuncts in selected cases but not first-line over ICD after arrest. Verapamil is ineffective, and genetic testing should not delay life-saving therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V – the vignette provides a single best answer. The clinical problem is a 27‑year‑old survivor of exercise‑triggered ventricular fibrillation (VF) with a borderline resting QTc of 460 ms and marked QT prolongation (QTc 510 ms) and polymorphic VT during recovery, plus a family history of sudden death. These findings point to congenital long‑QT syndrome (likely LQT1/LQT2). The keyed answer (A) – ICD implantation plus high‑dose β‑blocker – aligns with class I guideline recommendations for survivors of cardiac arrest from LQTS, offering both sudden‑death protection and arrhythmia suppression. The patient’s survival of a VF arrest fulfills a class I indication for ICD implantation for secondary prevention, and high‑dose β‑blockade remains the cornerstone of medical therapy for LQTS. Alternative B (nadolol + LCSD) is reserved for refractory cases, not first‑line post‑arrest. C (flecainide) is an adjunct for select genotypes, not primary therapy. D (verapamil) lacks efficacy in LQTS. E (genetic testing) should not delay life‑saving therapy. No internal contradictions or missing details prevent a unique best answer. Medical accuracy is consistent with current AHA/ACC/HRS guidance. No fix required; the item is board‑ready.\",\n\"medical_accuracy_score\": 5,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V – the vignette provides a single best answer. The clinical problem is a 27‑year‑old survivor of exercise‑triggered ventricular fibrillation (VF) with a borderline resting QTc of 460 ms and marked QT prolongation (QTc 510 ms) and polymorphic VT during recovery, plus a family history of sudden death. These findings point to congenital long‑QT syndrome (likely LQT1/LQT2). The keyed answer (A) – ICD implantation plus high‑dose β‑blocker – aligns with class I guideline recommendations for survivors of cardiac arrest from LQTS, offering both sudden‑death protection and arrhythmia suppression. The patient’s survival of a VF arrest fulfills a class I indication for ICD implantation for secondary prevention, and high‑dose β‑blockade remains the cornerstone of medical therapy for LQTS. Alternative B (nadolol + LCSD) is reserved for refractory cases, not first‑line post‑arrest. C (flecainide) is an adjunct for select genotypes, not primary therapy. D (verapamil) lacks efficacy in LQTS. E (genetic testing) should not delay life‑saving therapy. No internal contradictions or missing details prevent a unique best answer. Medical accuracy is consistent with current AHA/ACC/HRS guidance. No fix required; the item is board‑ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-010", "question": "A 7-year-old boy with sickle cell disease (HbSS) presents with acute onset of severe left hip pain and inability to bear weight. He had a pain crisis 2 weeks ago treated with IV opioids and hydration. Temperature is 38.3°C, HR 120/min, BP 96/58 mm Hg. Hip exam reveals extreme pain with any passive motion, especially internal rotation, and the leg is slightly flexed and externally rotated. WBC 18,000/µL, CRP 14 mg/dL, ESR 86 mm/h. Plain radiograph is unremarkable. MRI of the pelvis obtained within 6 hours of symptom onset shows bone marrow edema of the femoral head and neck with a moderate hip joint effusion, but no definite abscess or cortical destruction. Which is the most appropriate next step?", "options": ["Treat as vaso-occlusive crisis with IV opioids and observe for 24-48 hours", "Start broad-spectrum IV antibiotics and schedule urgent surgical hip drainage", "Obtain radionuclide bone scan to differentiate infarction from osteomyelitis", "Repeat pelvic MRI with contrast in 72 hours before deciding on surgery", "Start IV antibiotics and aspirate the hip joint under ultrasound guidance"], "answer": "E", "answer_index": 4, "explanation": "In children with sickle cell disease, distinguishing osteomyelitis/septic arthritis from bone infarction is challenging; fever, high inflammatory markers, inability to bear weight, and effusion demand prompt evaluation. Joint aspiration with culture, ideally under ultrasound guidance, plus empiric IV antibiotics is the appropriate next step to diagnose or exclude septic arthritis early. Delaying for observation or repeat imaging risks joint destruction; bone scan is nonspecific in this setting, and immediate surgical drainage without diagnostic aspiration may be premature without frank clinical sepsis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). The stem provides compelling, high-yield discriminators: fever (38.3°C), tachycardia (120/min), borderline hypotension (96/58 mm Hg), inability to bear weight, severe pain with passive internal rotation, flexed/externally rotated hip posture, marked leukocytosis (WBC 18,000/µL), CRP 14 mg/dL, and ESR 86 mm/h. MRI reveals bone marrow edema and a moderate hip effusion without abscess. In sickle cell disease, this constellation mandates urgent exclusion of septic arthritis. Option E—initiating empiric IV antibiotics combined with ultrasound-guided joint aspiration—uniquely satisfies both immediate therapeutic and diagnostic requirements. Alternative options are clearly inferior: A and D risk catastrophic joint destruction through observation or delayed imaging; B bypasses essential diagnostic confirmation; C is nonspecific and delays care. No secondary validity issues. The keyed answer is correct and fully defensible. Medical accuracy is gold-standard (score 5), reflecting current mainstream guidance that early aspiration is critical when infection cannot be excluded clinically. No medical inaccuracies or logical contradictions. Minimal fix: None required; the item is board-ready as written.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). The stem provides compelling, high-yield discriminators: fever (38.3°C), tachycardia (120/min), borderline hypotension (96/58 mm Hg), inability to bear weight, severe pain with passive internal rotation, flexed/externally rotated hip posture, marked leukocytosis (WBC 18,000/µL), CRP 14 mg/dL, and ESR 86 mm/h. MRI reveals bone marrow edema and a moderate hip effusion without abscess. In sickle cell disease, this constellation mandates urgent exclusion of septic arthritis. Option E—initiating empiric IV antibiotics combined with ultrasound-guided joint aspiration—uniquely satisfies both immediate therapeutic and diagnostic requirements. Alternative options are clearly inferior: A and D risk catastrophic joint destruction through observation or delayed imaging; B bypasses essential diagnostic confirmation; C is nonspecific and delays care. No secondary validity issues. The keyed answer is correct and fully defensible. Medical accuracy is gold-standard (score 5), reflecting current mainstream guidance that early aspiration is critical when infection cannot be excluded clinically. No medical inaccuracies or logical contradictions. Minimal fix: None required; the item is board-ready as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]